We serve Chemical Name:Pentyl 4-(dimethylamino)benzoate CAS:14779-78-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Pentyl 4-(dimethylamino)benzoate
CAS.NO:14779-78-3
Synonyms:Pentyl dimethyl PABA;Benzoic acid,4-(dimethylamino)-,pentyl ester;Padimatum;Amyl-p-dimethylaminobenzoate;Pentyl p-(dimethylamino)benzoate;Padimate A;EINECS 238-849-6;Amyl 4-(dimethylamino)benzoate;Amyl dimethyl paba
Molecular Formula:C14H21NO2
Molecular Weight:235.32200
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:343.4ºC at 760mmHg
Density:1.017g/cm3
Index of Refraction:1.524
PSA:29.54000
Exact Mass:235.15700
LogP:3.09960
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Pentyl dimethyl PABA chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Amyl dimethyl paba physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Padimate A Use and application,Amyl dimethyl paba technical grade,usp/ep/jp grade.
Related News: Microarrays of over 5,500 plasma membrane and secreted protein targets are expressed in human cells. Pentyl 4-(dimethylamino)benzoate manufacturer Drug manufacturers make medicines by mixing APIs and pharmaceutical excipients. Pentyl 4-(dimethylamino)benzoate supplier What is the difference? Raw material refers to chemical compounds that are used as a base to make an API. Pentyl 4-(dimethylamino)benzoate vendor Microarrays of over 5,500 plasma membrane and secreted protein targets are expressed in human cells. Pentyl 4-(dimethylamino)benzoate factory The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.
